Founders Financial Securities’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $1.05M | Buy |
21,884
+211
| +1% | +$10.8K | 0.05% | 303 |
|
|
2026
Q2 | $1.14M | Buy |
21,673
+528
| +2% | +$27.9K | 0.06% | 284 |
|
|
2026
Q1 | $1.23M | Buy |
21,145
+605
| +3% | +$32.8K | 0.07% | 251 |
|
|
2025
Q4 | $1.01M | Buy |
20,540
+1,560
| +8% | +$72.8K | 0.06% | 280 |
|
|
2025
Q3 | $819K | Buy |
18,980
+893
| +5% | +$34.9K | 0.06% | 275 |
|
|
2025
Q2 | $695K | Buy |
18,087
+760
| +4% | +$29K | 0.05% | 288 |
|
|
2025
Q1 | $659K | Sell |
17,327
-159
| -0.9% | -$5.82K | 0.06% | 277 |
|
|
2024
Q4 | $591K | Buy |
17,486
+513
| +3% | +$18.5K | 0.05% | 267 |
|
|
2024
Q3 | $694K | Sell |
16,973
-787
| -4% | -$32.2K | 0.06% | 223 |
|
|
2024
Q2 | $684K | Buy |
17,760
+542
| +3% | +$22.8K | 0.06% | 233 |
|
|
2024
Q1 | $738K | Buy |
+17,218
| New | +$710K | 0.08% | 206 |
|
|
2020
Q4 | – | Sell |
-11,370
| Closed | -$535K | – | 233 |
|
|
2020
Q3 | $535K | Sell |
11,370
-1,544
| -12% | -$77.4K | 0.17% | 88 |
|
|
2020
Q2 | $658K | Buy |
12,914
+891
| +7% | +$45.7K | 0.21% | 83 |
|
|
2020
Q1 | $569K | Sell |
12,023
-288
| -2% | -$15.4K | 0.21% | 66 |
|
|
2019
Q4 | $723K | Buy |
12,311
+38
| +0.3% | +$2.11K | 0.24% | 64 |
|
|
2019
Q3 | $655K | Buy |
12,273
+739
| +6% | +$38K | 0.21% | 78 |
|
|
2019
Q2 | $577K | Sell |
11,534
-2,064
| -15% | -$104K | 0.19% | 75 |
|
|
2019
Q1 | $710K | Sell |
13,598
-287
| -2% | -$14.3K | 0.23% | 72 |
|
|
2018
Q4 | $663K | Sell |
13,885
-665
| -5% | -$32.8K | 0.24% | 64 |
|
|
2018
Q3 | $731K | Sell |
14,550
-18
| -0.1% | -$915 | 0.2% | 70 |
|
|
2018
Q2 | $734K | Sell |
14,568
-267
| -2% | -$13.4K | 0.23% | 62 |
|
|
2018
Q1 | $725K | Buy |
14,835
+292
| +2% | +$13.6K | 0.23% | 62 |
|
|
2017
Q4 | $645K | Buy |
+14,543
| New | +$672K | 0.21% | 69 |
|
|
2017
Q1 | – | Sell |
-13,954
| Closed | -$672K | – | 103 |
|
|
2016
Q4 | $672K | Sell |
13,954
-16
| -0.1% | -$790 | 0.28% | 45 |
|
|
2016
Q3 | $753K | Sell |
13,970
-54,374
| -80% | -$2.98M | 0.32% | 47 |
|
|
2016
Q2 | $3.7M | Sell |
68,344
-382
| -0.6% | -$20.1K | 1.7% | 19 |
|
|
2016
Q1 | $3.48M | Buy |
+68,726
| New | +$3.42M | 1.64% | 18 |
|
|
2014
Q2 | – | Sell |
-25,339
| Closed | -$1.69M | – | 79 |
|
|
2014
Q1 | $1.69M | Buy |
25,339
+4,679
| +23% | +$316K | 1.13% | 24 |
|
|
2013
Q4 | $1.38M | Buy |
+20,660
| New | +$1.34M | 1.16% | 18 |
|
Other funds holding GSK
Founders Financial Securities's GSK Position: Q3 2026 in Review
Founders Financial Securities increased its GSK (GSK) stake by 0.97% in Q3 2026, buying an estimated $10.8K and bringing the position to 21,884 shares worth $1.05M. The position accounts for 0.05% of the portfolio, ranked #303.
Founders Financial Securities first reported a position in GSK in Q4 2013 and has held it in 29 quarters since. The position peaked at $3.7M in Q2 2016. 993 funds tracked by Wall St. Rank hold GSK as of Q3 2026.
- Founders Financial Securities held 21,884 shares of GSK worth $1.05M as of Q3 2026.
- Founders Financial Securities bought 211 GSK shares in Q3 2026, an estimated $10.8K.
- GSK made up 0.05% of Founders Financial Securities's portfolio in Q3 2026, its #303 holding.
- Founders Financial Securities first reported a position in GSK in Q4 2013 and has held it in 29 quarters since.
- Founders Financial Securities's GSK position peaked at $3.7M in Q2 2016.
- 993 funds tracked by Wall St. Rank held GSK as of Q3 2026.
Based on Founders Financial Securities's 13F filing for Q3 2026, filed 28 Oct 2026.